Custom service

Protein Expression and Purification Services

Gene to purified protein, in the host that suits the target.

Expression hosts: E. coli (BL21, Rosetta), Sf9/High Five, Pichia pastoris, HEK293, CHOScale: 10 µg to 10 g per batchPurity: >90% standard; >95% with polishing steps

The first decision in a protein project is the host, and it is usually made badly. A kinase expressed in E. coli will be insoluble or unphosphorylated; an antibody fragment expressed in insect cells will carry glycosylation it does not need; a secreted cytokine expressed in yeast will be hypermannosylated. Host choice is a technical judgement based on folding, post-translational modification and downstream use, not on convenience.

We run four systems. E. coli for cytosolic and periplasmic proteins at research scale, with tags chosen for solubility and purification rather than habit. Baculovirus-infected insect cells for proteins that need disulfide formation and limited glycosylation. Pichia pastoris for secreted proteins where the glycan profile is not critical and yield matters. HEK293 or CHO for anything that must be glycosylated, disulfide-linked and produced as it appears in a cell.

Purification is part of the same design, not a downstream step. The construct is built with a tag and a cleavage site chosen against the intended assay: His-tag for cheap capture, Strep for gentle native purification, GST or MBP where the protein will not fold without a solubility partner, no tag at all for reference standards. Every batch is delivered with purity, monomer content and activity data, because a protein that does not fold is not a deliverable.

This is the default entry point for most protein projects: reagents for assays, antigens for immunisation, substrates for enzymology and proteins for structural work. It covers everything from a first feasibility expression to gram-scale production.

It is not the right service when the protein is a membrane protein — those need detergent or nanodisc work from the first expression — or when the requirement is a documented production cell line for repeated supply. Both cases have dedicated services in this section.

Each batch ships with SDS-PAGE under reducing and non-reducing conditions, SEC-HPLC for monomer and aggregate content, A280 concentration, endotoxin by LAL where relevant, and an activity or binding assay where one exists. Soluble and insoluble fraction data from the expression screen are retained in the project report.

Service Highlights

  • Construct design first. Codon optimisation, domain boundaries, solubility tags and cleavage sites decided against the structure and the intended assay, not copied from a previous project.
  • Four expression systems. E. coli, baculovirus/insect, Pichia and mammalian cells under one roof, so a failing construct moves systems without changing vendor.
  • Tag and cleavage options. His, Strep, GST, MBP, SUMO and Fc, with TEV, 3C or thrombin cleavage and confirmation that the tag is gone by mass.
  • Parallel construct screening. Two to six truncation and tag variants expressed side by side at small scale before the preparative batch is committed.
  • Activity, not just purity. Where an assay exists — enzymatic, ligand-binding or cell-based — it is run on the final lot and reported with the SDS-PAGE.
  • Endotoxin control. LAL testing and removal available for every batch intended for cell assays or in vivo use.

How the work runs

  1. Target and host review

    Sequence, domains, expected modifications and intended use are reviewed, and the host is chosen with reasons stated rather than assumed.

  2. Construct design and synthesis

    Codon-optimised gene synthesised with the chosen tag and cleavage site; multiple boundary variants where the domain edges are uncertain.

  3. Small-scale expression screen

    Test expressions in flasks or deep-well plates, analysed by SDS-PAGE and soluble/insoluble fractionation, to pick the construct and condition.

  4. Preparative expression

    Scale-up under the selected condition — shaker flask, fermenter, or bioreactor — with harvest at peak viability or density.

  5. Purification

    Affinity capture, tag cleavage where required, ion exchange or SEC polishing, and buffer exchange into the requested formulation.

  6. QC and release

    SDS-PAGE, SEC-HPLC, A280, endotoxin, and activity assay where available, with a certificate of analysis.

Specifications & timeline

Expression hosts
E. coli (BL21, Rosetta), Sf9/High Five, Pichia pastoris, HEK293, CHO
Scale
10 µg to 10 g per batch
Purity
>90% standard; >95% with polishing steps
Tags
His, Strep, GST, MBP, SUMO, Fc; removable by TEV or 3C protease
Timeline
3–6 weeks depending on host and purification depth

Related Products

Next step

Tell us the target, we will tell you what is feasible

Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.